“Hospital Infection Therapeutics Market | Latest Growing Trends and Opportunities Analysis Report - BioSpace” plus 1 more

---

Hospital Infection Therapeutics Market | Latest Growing Trends and Opportunities Analysis Report - BioSpace Posted: 29 Nov 2020 09:38 PM PST The report examines the past and current growth scenario in the global hospital infection therapeutics market to present an exhaustive analysis of growth trends and opportunities in the said market for the 2019 – 2029 forecast period. The report includes an elaborate executive summary, along with a market synopsis that covers information on key segments considered in the scope of this study. Furthermore, the executive summary section covers market size, trends, and opportunities in key regions of the hospital infection therapeutics market. An in-depth qualitative and quantitative analysis of demand drivers, challenges, and competitive landscape is also covered in the executive summary section of hospital infection therapeutics market. Key companies operating in the hospital infection therapeutics market along with an overview of their growth strategies is covered in this section. The market overview section covers the regional outlook of the hospital infection therapeutics market. Market attractiveness analysis of key regions along with market size projections of key regions for the forecast period are covered in this section. Request a sample to get extensive insights into the market @ https://www.tmrresearch.com/sample/sample?flag=S&rep_id=6939 The report is compiled in a chapter-wise layout for reading comprehensibility. The report includes an array of graphs and tables for pictorial representation. The report is prepared using standard research methodologies, including Porter's Five Forces analysis and SWOT analysis. A combination of primary and secondary research makes the report on the hospital infection therapeutics market a valuable tool. Analysts employed bottom-up approach for determining the market size using various indicators gathered from secondary sources, including population in 2017, variations in cost of therapeutics across major regions, prevalence of all types of hospital acquired infections in developed countries, and approval of therapeutics in specific regions. Top-down approach employed to obtain the market size for therapeutic segments, wherein revenues of all publicly listed companies were gathered through secondary sources. Moreover, historical year-on-year growth has been considered while estimating the market size. The market size forecast in terms of US$ Mn for each segment has been provided for the 2019 – 2029 forecast period, considering 2017 as the base year. Hospital Infection Therapeutics Market: Key Segments The hospital infection therapeutics market has been segmented based on infection, therapeutics, and region. By therapeutics, key segments into which the hospital infection therapeutics market is divided are anti-bacterial drugs, anti-viral drugs, anti-fungal drugs, and others. The anti-bacterial drugs segment is sub-segmented into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. Key sub-segments within anti-fungal drugs segment are Amphotericin B, Caspofungin, and others. Based on infection, key segments into which the hospital infection therapeutics market is divided are urinary tract infections, hospital acquired pneumonia, bloodstream infections, gastrointestinal disorders, surgical site infections, and other hospital infections. Hospital Infection Therapeutics Market: Regional Outlook In terms of region, the hospital infection therapeutics market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The report provides market size and growth rate projections for each of these segments for the 2018 -2026 forecast period. Furthermore, the report provides market size and growth rate projections for major countries in each region for the 2019 – 2029 forecast period. Hospital Infection Therapeutics Market: Companies Mentioned Key players operating in the hospital infection therapeutics market include Merck & Co. Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Bayer AG plc, Gilead sciences Inc., Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Sanofi S.A., and Basilea Pharmaceutica Ltd among others. Each of the companies is profiled for their business overview, product portfolio, financial standing, and SWOT analysis. Ask An Analyst @ https://www.tmrresearch.com/sample/sample?flag=ASK&rep_id=6939 About TMR Research TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today's supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients' conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends. Contact: Rohit Bhisey TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States Tel: +1-415-520-1050 Visit Site: https://www.tmrresearch.com/

QLGN: Testing AS1411 as COVID-19 Treatment… - Zacks Small Cap Research Posted: 30 Nov 2020 11:40 AM PST By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update AS1411 Clinical Trial in COVID-19 to Initiate 1H21 On October 28, 2020, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) announced a positive pre-IND meeting with the U.S. FDA regarding the development of AS1411 as a treatment for COVID-19. AS1411 is a DNA aptamer that has exhibited antiviral activity in a number of different in vitro assays against different viruses. The following manuscripts show that AS1411 is active against a number of different RNA viruses, including dengue virus, human immunodeficiency virus (HIV), and respiratory syncytial virus (RSV). We believe that the following studies provide proof-of-concept for AS1411 as an anti-viral agent, nucleolin as an antiviral target, and justify testing AS1411 as a treatment for SARS-CoV-2 infection. • Balinsky et al., 2013: The dengue virus capsid protein is a structural component of the infectious virion, and it interacts with and colocalizes with nucleolin. Both knockdown of nucleolin expression with siRNA and treatment with AS1411 caused a significant reduction in viral titers following dengue virus infection. There was no change in viral RNA or protein levels at early time points post-infection, thus nucleolin is likely involved in viral morphogenesis. • Perrone et al., 2016: Cell-surface nucleolin is a low-affinity co-receptor for HIV on target cells, thus since AS1411 binds to nucleolin it was tested as a potential anti-HIV therapy. AS1411 inhibited HIV attachment and entry into target cells along with antiviral activity without displaying cytotoxicity. • Mastrangelo et al., 2017: Following administration of AS1411 to RSV-infected mice and rats there was a reduction in lung viral titers, decreased airway inflammation, and decreased IL-4/IFN-g ratios compared to untreated, infected animals. The FDA recommended a Phase 2a proof-of-concept study to evaluate safety and initial efficacy at Day 28 of AS1411 in COVID-19 patients along with determining an appropriate dose to move into a Phase 2b trial. We anticipate the company initiating the Phase 2a trial in the first half of 2021. In June 2020, Qualigen entered into an exclusive license agreement with the University of Louisville to develop AS1411 as a treatment for COVID-19. The company is working with the University to complete pre-IND studies such that an IND can be filed in early 2021. In September 2020, Qualigen and the University filed a provisional patent application entitled "Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent." Qualigen also recently announced a manufacturing agreement with STA Pharmaceutical Co., a subsidiary of WuXi AppTec, for cGMP production of AS1411 to ensure adequate supply for anticipated clinical trials in COVID-19 patients. Expands Research Agreement for ALAN On October 1, 2020, Qualigen announced it entered into an amended Sponsored Research Agreement with the University of Louisville regarding the company's anti-cancer drug candidate ALAN. The original agreement encompassed animal studies to assess the safety and efficacy of ALAN compositions designed to treat pediatric and adult acute myeloid leukemia (AML). The amended agreement includes testing ALAN for additional indications including glioblastoma and non-small cell lung cancer. ALAN (Aptatmer-Linked Anti-Nucleolin) is an aptamer-based anticancer compound composed of AS1411 attached to gold nanoparticles. Previous preclinical studies showed that ALAN was stable in aqueous and serum-containing solutions, had superior cellular uptake, and increased antiproliferative effects compared to unconjugated AS1411. Financial Update On November 13, 2020, Qualigen announced financial results for the second quarter of fiscal year 2021 that ended on September 30, 2020. Total revenues for the three months ending September 30, 2020 were $0.8 million compared to $1.2 million for the same period in 2019. The decrease was primarily due to the COVID-19 pandemic, which resulted in a decreased number of patient visits to physician offices, clinics, and small hospitals. All revenue was derived from the sale of diagnostic products. G&A expenses for the second quarter of fiscal year 2021 were $2.7 million compared with $0.2 million for the second quarter of fiscal year 2020. The increase is primarily due to the addition of expenses associated with being a publicly traded company during the current period. R&D expenses for the three months ending September 30, 2020 were $0.9 million compared to $0.2 million for the prior-year period. The increase was primarily due to advancing the development pipeline along with work related to the COVID-19 antibody diagnostic test and FastPack PRO instrument. Net loss for the second quarter of fiscal year 2021 was $8.1 million, or $0.41 per share, compared with a net loss of $0.4 million, or $0.06 per share, for the second quarter of fiscal year 2020. The net loss in the most recent quarter included a non-cash charge of $4.4 million for the change in fair value of warrant liabilities along with non-cash charges of $1.2 million for stock-based compensation. Loss from operations for the three months ending September 30, 2020 was $3.7 million compared to $0.3 million for the months ending September 30, 2019. As of September 30, 2020, Qualigen had approximately $14.5 million in cash and cash equivalents. We estimate this is sufficient to fund operations through calendar year 2021. As of November 5, 2020, Qualigen had approximately 23.1 million shares outstanding and, when factoring in stock options and warrants, a fully diluted share count of approximately 37.5 million. Conclusion Since we initiated on Qualigen in September 2020 the company continues to execute on its business plan, as evidenced by the positive feedback from the FDA regarding the clinical development plan for AS1411 in COVID-19 patients. We anticipate an IND being filed for AS1411 in COVID-19 in early 2021 such that a Phase 2a trial can initiate by mid-2021. In addition, we are glad to see the expanded agreement with the University of Louisville regarding ALAN and look forward to additional updates as the company advances it toward the clinic later in 2021. With no changes to our model our valuation remains at $10 per share. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.  DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.

You are subscribed to email updates from "infection inc" - Google News. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States